Jane Griffiths Joins TB Alliance Board of Directors
NEW YORK (February 3, 2020)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has
NEW YORK (February 3, 2020)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has
January 30, 2020—The 2019 G-FINDER report indicates that global investment in tuberculosis (TB) research and development (R&D) levels remain far
NEW YORK (January 29, 2020)—TB Alliance and partners announced the launch of the ERA4TB (European Regimen Accelerator for Tuberculosis) project
NEW YORK (January 27, 2020)—New peer-reviewed research has evaluated the efficacy of different doses and schedules of linezolid for the treatment
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
TB Alliance applauds the Stop TB Partnership’s TB REACH program for investing in efforts to combat tuberculosis (TB). The $15.4